Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

6

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Purinergic receptor P2Y12

6

platelet aggregation

6

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2009

6

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Cardiovascular diseases

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Daiichi Sankyo|Ube Industries

6

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

6

FDA UNII

6

PUBCHEM

6

SMS_ID

4

CHEBI

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

BLOOD AND BLOOD FORMING ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTITHROMBOTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTITHROMBOTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Platelet aggregation inhibitors excl. heparin

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

PRASUGREL

34K66TBT99

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2009

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Purinergic receptor P2Y12

platelet aggregation

Conditions:

Cardiovascular diseases

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformatio...

n in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed under the brand name EFFIENT in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

PRASUGREL BESYLATE

7KYD4NE018

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2009

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Purinergic receptor P2Y12

platelet aggregation

Conditions:

Cardiovascular diseases

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformatio...

n in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed under the brand name EFFIENT in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

PRASUGREL SULFATE

K9GA2EPK9H

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2009

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Purinergic receptor P2Y12

platelet aggregation

Conditions:

Cardiovascular diseases

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformatio...

n in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed under the brand name EFFIENT in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

PRASUGREL MALEATE

VC4YSF7KNU

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2009

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Purinergic receptor P2Y12

platelet aggregation

Conditions:

Cardiovascular diseases

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformatio...

n in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed under the brand name EFFIENT in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

PRASUGREL HYDROBROMIDE

4XFT5Y771R

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2009

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Purinergic receptor P2Y12

platelet aggregation

Conditions:

Cardiovascular diseases

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformatio...

n in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed under the brand name EFFIENT in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

PRASUGREL HYDROCHLORIDE

G89JQ59I13

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2009

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Purinergic receptor P2Y12

platelet aggregation

Conditions:

Cardiovascular diseases

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformatio...

n in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed under the brand name EFFIENT in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1